NCT07873164|Not Yet Recruiting
Vagal Auricular Stimulation for Motion Sickness
VAMOS
Central Mechanisms of Nausea and Their Modulation Via Non-invasive Neurostimulation
Loading search results
VAMOS
Central Mechanisms of Nausea and Their Modulation Via Non-invasive Neurostimulation
Sponsor study identifier
Secondary identifiers
NIH
interventional
115
1 country
1
Study Start
September 24, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
September 24, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 24, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study aims to understand the mechanisms underlying nausea response in the brain stem, and the effect of vagal nerve stimulation on nausea.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 24, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 7, 2026
Actual (reported)October 14, 2026
Actual (reported)September 24, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
September 24, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
September 24, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Simulator Sickness Questionnaire (SSQ), Nausea subscale
0 (not at all) is the minimum, 3 (severe) is the maximum. Higher scores mean a worse outcome: a higher score means the participant reported more nausea symptoms.
2 hours
This group will receive active stimulation during the motion sickness paradigm of the first MRI, and sham stimulation during the motion sickness paradigm of the second MRI.
This group will receive sham stimulation during the motion sickness paradigm of the first MRI, and active stimulation during the motion sickness paradigm of the second MRI.
MRI safe vagal nerve stimulation during motion sickness inducing paradigm.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Spaulding Rehabilitation Hospital, 300 First Avenue
Boston, Massachusetts, 02129, United States
First Submitted
October 7, 2026
First Posted
October 14, 2026
Study Start
September 24, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
Contact the study team to confirm eligibility.
September 24, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 24, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 16, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: